| Literature DB >> 18428185 |
Ulli Rothweiler1, Anna Czarna, Marcin Krajewski, Jolanta Ciombor, Cédric Kalinski, Vladimir Khazak, Günther Ross, Natalia Skobeleva, Lutz Weber, Tad A Holak.
Abstract
p53 has been at the centre of attention for drug design since the discovery of its growth-suppressive and pro-apoptotic activity. Herein we report the design and characterisation of a new class of isoquinolinone inhibitors of the MDM2-p53 interaction. Our identification of druglike and selective inhibitors of this protein-protein interaction included a straightforward in silico compound-selection process, a recently reported NMR spectroscopic approach for studying the MDM2-p53 interaction, and selectivity screening assays using cells with the same genetic background. The selected inhibitors were all able to induce apoptosis and the expression of p53-related genes, but only the isoquinolin-1-one-based inhibitors stabilised p53. Our NMR experiments give a persuading explanation for these results, showing that isoquinolin-1-one derivates are able to dissociate the preformed MDM2-p53 complex in vitro, releasing a folded and soluble p53. The joint application of these methods provides a framework for the discovery of protein interaction inhibitors as a promising starting point for further drug design.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18428185 DOI: 10.1002/cmdc.200800025
Source DB: PubMed Journal: ChemMedChem ISSN: 1860-7179 Impact factor: 3.466